SCHEMBL6410197

SCHEMBL6410197

CC(F)(F)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12224296 1.00 LIPA (0.32)
SCHEMBL13640707 0.90 LIPA (0.42)
SCHEMBL23570077 0.87
SCHEMBL765362 0.86
SCHEMBL6114283 0.86
SCHEMBL2450112 0.85 TSHR (0.33)
SCHEMBL2449244 0.85 TSHR (0.33)
SCHEMBL2449842 0.85 TSHR (0.33)
SCHEMBL1034374 0.83 PDK1 (0.34)
SCHEMBL18068060 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303495-A9 PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) 2023-09-28 US disclosed
EP-3694858-B1 BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2023-01-11 EP disclosed
EP-3759096-B1 CD73 INHIBITORS LILLY CO ELI (US) 2022-02-16 EP disclosed
WO-2021252307-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-12-16 WO disclosed
US-20210277003-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-09-09 US disclosed
WO-2021047622-A1 PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海济煜医药科技有限公司 2021-03-18 WO disclosed
WO-2020249791-A1 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 WO disclosed
EP-3677579-A1 HETEROCYCLIC GLS1 INHIBITORS Board of Regents, The University of Texas System (US) 2020-07-08 EP disclosed
EP-3164394-B1 GLS1 INHIBITORS FOR TREATING DISEASES UNIV TEXAS (US) 2020-04-01 EP disclosed
WO-2019079632-A1 GLUTAMINASE INHIBITOR THERAPY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-04-25 WO disclosed
US-20080262036-A1 Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
US-20050053552-A1 Phase shift colloids as ultrasound contrast agents QUAY STEVEN C (US) 2005-03-10 US disclosed
US-6569404-B1 Aqueous colloidal suspension, dispersed phase is gas microbubbles of perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane or sulfur hexafluoride; fluorinated amphiphile for stabilizing microbubbles AMERSHAM HEALTH A/S (NO) 2003-05-27 US disclosed
US-6245319-B1 Colloidal dispersions of perfluoropentane SONUS PHARMACEUTICALS, INC. 2001-06-12 US disclosed
EP-0680341-B1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMA INC (US) 2001-05-09 EP disclosed
EP-1038535-A2 Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents SONUS PHARMACEUTICALS, INC. (US) 2000-09-27 EP disclosed
US-5876696-A Composition comprising a fluorine containing surfactant and perfluoropentane for ultrasound SONUS PHARMACEUTICALS, INC. (US) 1999-03-02 US disclosed
US-5558853-A WATER IMMISCIBLE FLUORINE COMPOUND SONUS PHARMACEUTICALS (US) 1996-09-24 US disclosed
EP-0680341-A1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMACEUTICALS, INC. (US) 1995-11-08 EP disclosed
WO-1994016739-A1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMACEUTICALS, INC. (US) 1994-08-04 WO disclosed